DIALOG(R) File 351: Derwent WPI

(c) 2001 Derwent Info Ltd. All rts. reserv.

003542371

WPI Acc No: 1982-90363E/198242

Mfg. pure antigen from non-A, non-B hepatitis virus - useful as

diagnostic reagents

Patent Assignee: TREPO C (TREP-I)

Inventor: TREPO C

Number of Countries: 013 Number of Patents: 005

Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Week	
WO 8203330	Α	19821014				198242	В
FR 2502154	A	19820924				198245	
EP 74986	Α	19830330	EP 82900965	A	19820330	198314	
EP 74986	В	19850918				198538	
DE 3266294	G	19851024	•			198544	

Priority Applications (No Type Date): FR 816385 A 19810330

Patent Details:

Patent No Kind Lan Pg Main IPC Filing Notes

WO 8203330 A F 65

Designated States (National): JP SU US

Designated States (Regional): AT BE CH DE FR GB LU NL SE

EP 74986 A F

Designated States (Regional): AT BE CH DE FR GB LU NL SE

EP 74986 B F

Designated States (Regional): AT BE CH FR GB LI LU NL SE

Abstract (Basic): WO 8203330 A

Prodn. of purified antigens from non-A, non-B (NANB) hepatitis virus comprises first ultracentrifuging appropriate sera or liver extracts to concentrate the virus in the pellet. This is incubated for 1-24 hr. at 0-37 deg.C with a nonionic detergent, then a fraction contg. purified NANBc antigen isolated. Opt. this fraction is further incubated for 1-24 hr. at 0-37 deg.C with an ionic detergent to isolate NANBe antigen.

Two other purification procedures are claimed. (A) any virus particles are eliminated from an appropriate serum sample (pref. by ultracentrifuging), then gamma-globulino removed, the antigen conc. (pref. by pptn.) and then chromatography on a support to which heparin is bonded. Elution is with aq. NaCl soln. of increasing concn. and salts are removed conventionally from the eluate. These antigens, and their associated antibodies, are used in diagnosis of NANB viral hepatitis and for monitoring the progress of the disease.